personalia |
|
|
|
|
J Almeda1, J Casabona1, B Simon1, M Gerard2, D Rey3, V Puro4, T Thomas5
1. CEESCAT, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
2. Division of Infectious Diseases, C.H.U. Saint Pierre, Brussels, Belgium
3. Observatoire Regional de la Santa, ORS PACA, Marseilles, France
4. Dept.of Epidemiology of the National Institut of Infect.Diseases. INMI "L. Spallanzani" IRCSS, Rome, Italy
5. Public Health Laboratory Service Communicable Disease Surveillance Centre, London, United Kingdom
Post-exposure prophylaxis (PEP) is the standard of care for a healthcare worker (HCW) accidentally exposed to an HIV infected source person (occupational exposure), but this is not the case for non-occupational exposures. Very few national guidelines exist for the management of non-occupational exposures to HIV in Europe, contrarily to the occupational ones. The administration of non-occupational post-exposure prophylaxis (NONOPEP) for HIV may be justified by: a biological plausibility, the effectiveness of PEP in animal studies and occupational exposures in humans, efficacy in the prevention of mother to child HIV transmission, and cost effectiveness studies. These evidences, the similar risk of HIV transmission for certain non-occupational exposures to occupational ones, and the conflicting information about attitudes and practices among physicians on NONOPEP led to the proposal of these European recommendations. Introduction Post-exposure prophylaxis (PEP) is now the standard of care when a healthcare worker (HCW) is accidentally exposed to a source person known to be infected with HIV (occupational exposure), but this is not the case for non-occupational exposures. We considered as non-occupational exposure all accidental and sporadic incidents in which contact with blood or other body fluids (semen, vaginal secretions, etc.) that pose a potential risk for HIV infection occurred, excluding exposures of HCWs in a healthcare or laboratory setting. Non-occupational exposure includes unprotected sexual exposure, sexual exposure involving a broken or slipped condom, injecting drug users (IDUs) sharing equipment, accidental needlestick injuries, bite wounds, mucosal exposure, etc. Exposure to tears or sweat is not considered to be a risk for HIV transmission. Although there have been no prospective controlled trials or retrospective case-control studies to support its potential efficacy, non-occupational post-exposure prophylaxis (NONOPEP) is used increasingly frequently. Faced with a request for NONOPEP for HIV, physicians must deal with several questions such as the magnitude of the risk of the exposure or whether or not to prescribe antiretroviral therapy (ART). NONOPEP demand is not negligible in Europe [1-3], nor is it in other parts of the world [4-8]. Several questions regarding the prescription of NONOPEP remain unanswered, however, including which combination of antiretrovirals to choose, the duration of the follow up, and which laboratory tests are necessary. Curiously, guidelines for the management of occupational HIV exposures exist in the United States and in most European countries; yet very few national guidelines for the management of possible sexual, injecting drug use, or other non-occupational exposures to HIV have been developed in Europe [9]. Background Several factors justify the administration of NONOPEP:
1. One of the characteristics regarding the pathogenesis of HIV infection is the period of time between the HIV exposure and the replication of the virus in the lymph nodes [10]. Immediately after HIV exposure, there is an infection of dendritic cells at the site of the inoculation. These infected cells will migrate to the regional lymph nodes during the first 24-48 hours [11]. The beginning of HIV systemic infection is marked by the settlement of the infected dendritic cells in the lymph nodes. In theory, administering ART as a prophylaxis during this period and before the lymph node settlement could prevent the establishment of a systemic infection. 2. The results of different animal studies have shown plausibility in preventing HIV infection, by administering ART after an exposure to HIV [12]. In 1995, the results of a study showing the prevention of SIV infection in macaques were published. Administering an antiretroviral compound (PMPA (tenofovir)) 24 hours after virus inoculation, for four weeks, prevented SIV infection in all of the macaques. Protection was incomplete if tenofovir was administered at 48 or 72 hours after the exposure, or if the duration of treatment was 3 or 10 days only. This suggests that the earlier ART is given, the more effective the prevention [13]. In 2000, Otten et al published data from a study in which macaques received an atraumatic intravaginal inoculum of HIV-2. One group of macaques did not receive ART, the second group received tenofovir 12 hours after the exposure, the third at 36 hours, and the fourth at 72 hours. In the first group, all but one of the macaques became infected. None of the macaques from the second and third group became infected, and one in three macaques in the fourth group became infected after 16 weeks. These data confirm that the time elapse between the exposure and the beginning of ART is an important factor which can affect NONOPEP efficacy, and support the need for an adequate follow up period after NONOPEP to monitor for delayed seroconversions [14]. In a retrospective case-control study, AZT given after an occupational percutaneous exposure to a HCW was associated with an 81% decrease in the risk of HIV infection. Another issue raised by this study was the increase in the risk of acquiring HIV when some enhancing factor existed, such as the depth or extent of the injury, the presence of visible blood on the device, or an advanced stage of HIV disease in the source person [15]. 3. Data from human studies regarding the prevention of mother to child HIV transmission also support the probability of the efficacy of an HIV post-exposure prophylaxis. In a randomised trial, the administration of AZT to HIV infected pregnant women was associated with a 2/3rd reduction in HIV infections in babies whose mothers had been given AZT pre and intra partum (and who themselves had received AZT post partum) versus those randomised to placebo [16]. Despite contact between the child's blood and the HIV status of its mother, AZT prevented infection in the majority of cases. 4. In 1997, an article was published describing the cost effectiveness of tritherapy with zidovudine, lamivudine and indinavir following moderate to high risk occupational exposure [17]. Another cost effectiveness study on post-exposure prophylaxis following potential sexual HIV exposure in humans concluded that in the following cases PEP is cost effective: receptive anal sex when it is almost certain that the source person is infected, and receptive vaginal sex only when the source person is known to be HIV positive [18]. Assuming that it is not only cost effectiveness that can predominate in a public health decision, further studies are necessary. The above mentioned studies encouraged us to propose and standardise this prophylaxis for non-occupational exposure, despite some difficulties, including the extrapolation of animal study data to humans, the specificity of the mother to child transmission, the difference between occupational and non occupational exposures, the difficulty of the risk assessment in non occupational exposure, the reports of PEP failures to prevent HIV infection after occupational exposure in at least 21 instances with different ART [19-23]. Another argument for introducing NONOPEP guidelines is the results of a French study in which the existence of NONOPEP recommendations at national level had an impact on physicians' behaviour, improving their acceptance of and attitude towards NONOPEP [24] and probably on their risk assessment. Furthermore, a survey about knowledge of, attitudes towards and practices of NONOPEP for HIV has been conducted among European physicians, as part of the same project that led to the present recommendations [25]. The results clearly showed that in the countries with national guidelines there were significantly more prescriptions made following requests for NONOPEP (76% versus 61%, p=0.007), as well as more antiretroviral emergency starter kits available (92% versus 44%, p<0.001). Similarly, the exposure risk assessment and the management of NONOPEP requests improved among this group of physicians in comparison with the group without national guidelines. Finally, the probability of HIV transmission by certain non-occupational exposures is estimated to be higher than the risk of percutaneous occupational exposure. Furthermore, the characteristics of both situations - occupational and non-occupational - are different. In the case of occupational exposures, it is possible to start ART earlier, the HIV status of the source is usually known, and the follow up of the exposed person is more feasible. In the case of a non-occupational exposure, however, the time delay between exposure and ART initiation is frequently longer, the possibility of knowing the HIV status of the source person is lower, and the rate of lost-to-follow-up is higher, hence the need for specific guidelines for these non-occupational exposure situations. Methods In September 2001, the European Commission (Directorate-General for Health and Consumer Protection, (DG-SANCO)) funded a project on non-occupational post-exposure prophylaxis to HIV (Euro-NONOPEP Project - project number 2000CVG4-022), coordinated by the Centre d'Estudis Epidemiol?gics sobre la Sida de Catalunya (Center for Epidemiological Studies on HIV/AIDS of Catalonia, CEESCAT), with the participation of 14 European countries. One of the main objectives of this project was the development of the European recommendations regarding the management of HIV NONOPEP. In this perspective, the national representatives from each participant country were contacted and integrated into the project, on the basis that they were responsible for the national registry or multicentre group, or had been designated by national healthcare agencies. The representatives of participating member countries were acknowledged to be experts in the field of bloodborne pathogen transmission prevention and PEP. A steering committee was established to take responsibility for the logistic and scientific aspects of the project, with participation of members from five of the participating countries (Spain, France, the United Kingdom, Italy and Belgium). Concerning the development of the European recommendations, the steering committee members reviewed previous recommendations, risk assessment, possible prophylaxis regimens and their cost effectiveness, and shared and updated information at three meetings, in December 2000, June 2001 and December 2002. For this review, data from the published literature and abstracts from recent scientific conferences were taken into consideration. Reviewed data were presented and discussed by representatives of all participant countries in the project during the first of a two day workshop on 19-20 October 2001. The national representatives were divided into two working groups, one to achieve consensus on the risk assessment of non-occupational post-exposure prophylaxis, and the other to achieve consensus on the treatment and clinical follow up protocols for non-occupational post-exposure prophylaxis. The results are presented in this paper. Results and discussion Literature review on risk exposure assessment.- Table 1 shows the different risk estimates of HIV transmission by non-occupational exposures, according to a literature review. It is important to remember that these estimates of transmission are not absolute. Every risk exposure depends on the type of exposure, but also on cofactors such as follows: a) infectivity of the source, taken as a high plasma viral load, increases the risk of transmission in all cases [37]; b) genito-oral ulcers, sexually transmitted infections or bleeding increase the risk of transmission for a sexual exposure [34], and c) for accidental needlestick exposures, fresh blood, a deep injury or intravenous injection all increase the risk of HIV transmission [15]. Some of the reviewed articles in the literature about estimates on transmission risk of insertive vaginal and anal sex come from North America, where a high proportion of men are circumcised. Therefore the risk for uncircumcised men may be underestimated. When the HIV status of the source person is unknown, the risk assessment is usually based on the type of exposure, on the estimated HIV prevalence in the source HIV group and/or the HIV prevalence in the source person's country of origin. Recommendations In general, physicians facing a request for non-occupational
post-exposure prophylaxis to HIV should take the following steps:
The indications of NONOPEP for sexual, IDU, needlestick and other exposures are shown in boxes 1 to 4 respectively, according to the criteria expressed by the consensus group. It should be stated that at-risk sexual exposures are 'unprotected intercourse', either without condom or with broken or slipped condom. Guidelines for the treatment of HIV infection recommend the use of three drugs [39]. It is supposed that a three drug therapy will also be the most effective in the case of NONOPEP, when there is a real risk of HIV transmission. Any complete treatment has to take four weeks duration. Looking at the treatment combination, tritherapy (treatment with a combination of three drugs belonging to two different classes) is recommended; bitherapy (treatment with two nucleoside reverse transcriptase inhibitors (NRTI)) may also be an option. In general, any combination of drugs available for HIV infected patients can be used as PEP and the simplest and least toxic regimens are to be preferred. When the source person has unknown HIV status, or is HIV positive but not treated, or HIV positive with an efficient first line therapy, the NONOPEP treatment recommended for the patient as first line treatment is 2 NRTI (a) + 1 protease inhibitor (PI) (b) or efavirenz, being the NRTI combinations zidovudine + lamivudine; or stavudine + lamivudine; and the PI, nelfinavir; or indinavir; or lopinavir/ritonavir combination. Several remarks were made with respect to the NONOPEP:
For a second line of prophylaxis, two possibilities arise: if the source person is HIV positive and has been treated by ART with any failure of treatment in his/her history (actual or previous), the NONOPEP must be adapted to the drug history and/or to resistance testing if available, and abacavir may be an option in this case. However, if the source person is HIV positive and has been treated by ART without treatment failure, and has an undetectable viral load, the same ART as that of the source person can be used. Table 2 shows the patient follow up schedule established
by consensus, but some remarks were made with respect to follow up:
According to the consensus process presented, the risk assessment and prescription of antiretroviral post-exposure prophylaxis can be made and prescribed in specific non-occupational situations of risk for HIV transmission that seem to be frequent in clinical practice. Most of the points and agreements expressed in these recommendations have been achieved by consensus, on the basis of indirect evidence, and some remain controversial; the maximum time elapsed from exposure to prescription may be reduced to 36 hours; the prevalence limit for unknown HIV status of source person may vary; biotherapy regimens should be considered more frequently, follow up schedule may be varied or shortened, etc. For this reason, the working group thinks that these recommendations should be reviewed and updated periodically according to new knowledge and evidence, if any. Standardised recommendations have proved useful for improving counselling and care to HIV exposed individuals. However, every country is free to adapt these recommendations to its own HIV infection epidemiological situation, and its own NONOPEP policies, especially regarding the indications named as 'PEP is considered'. In fact several national recommendations for NONOPEP issued by ministries of health in Greece, Italy, Portugal and Spain were promoted following these European recommendations, adding to other previous and updated ones (Austria, France, Germany, Luxembourg, Sweden). In any case, the final decision for NONOPEP prescription
must be made on the basis of the patient-physician relationship, bearing
in mind that NONOPEP should never be considered as a primary prevention
strategy.
* Euro-NONOPEP Project Group Members: Brigitte Schmied, Piotr Cich?n (Vienna, Austria), Stephane De Wit (Brussels, Belgium), Else Smith, Suzanne Lunding (Copenhagen, Denmark), Patricia Enel, Karim Ben Diane (Marseilles, France), Ulrich Marcus (Berlin, Germany), Nikos Mangafas, M Lazanas (Athens, Greece), Colm Bergin (Dublin, Ireland), Anneke Van Den Hoek (Amsterdam, the Netherlands), Gabriella De Carli (Rome, Italy), Carlos Alves, Antonio Mota Miranda (Porto, Portugal), Janez Tomazic (Ljubljana, Slovenia), Beatriz Marincovich (Badalona, Spain), Enos Bernasconi, Bea Bernasconi (Lugano, Switzerland), Katharine Sadler (London, United Kingdom). References 1.Rabaud C, Bevilacqua
S, Beguinot I, Dorvaux V, Schumacher H, May T, Canton P. Tolerability of
postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for
human immunodeficiency virus infection. Clin Infect Dis. 2001 May
15;32(10):1494-5.
|
обсудить на ReForum+ |
|
|
|